Seattle juggernauts Fred Hutch Cancer Research Center and Amazon are joining forces to develop early-stage cancer vaccine trials.
Fred Hutch will leverage Amazon’s machine learning expertise for the trials, which will center around the safety of a vaccine for people with late-stage melanoma and breast cancer resistant to treatment. Phase I of the trial has a completion date of Nov. 1, 2023.
“It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial,” said an Amazon spokesperson. “This will be a long, multi-year process — should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.”